Shaofu Ma 1), Yoshitaka Koshino 2), Satoko Yamamoto 1), Takeo Shimasaki 1), NaohisaTomosugi 1)
|
|
- Christian Hill
- 6 years ago
- Views:
Transcription
1 J Kanazawa Med Univ , 2016 Rapid Increase in Serum Iron Level After Oral Iron Intake as an Indicator of Duodenal Iron Absorption and Inverse Regulation of Iron Absorption by Hepcidin Expression Shaofu Ma 1), Yoshitaka Koshino 2), Satoko Yamamoto 1), Takeo Shimasaki 1), NaohisaTomosugi 1) Abstract: Objective: Hepcidin is a hepatocyte-derived peptide that is thought to be involved in the regulation of intestinal iron absorption. Ferric citrate is a phosphate binder with additional effects on iron absorption. Better understanding of iron absorption under various levels of hepcidin may improve ferric citrate supplementation in individuals with renal anemia. We provide a new method to predict the individual iron absorption ability of the duodenum. Methods: Rats on an ordinary diet were given 10 mg of ferric citrate, and the serum concentrations of hepcidin and iron were monitored for 24 hours. Rats with hepcidin levels induced by using alternative methods such as bloodletting or intravenous iron loading were also given ferric citrate, and serum iron level was measured at 2 hours after oral iron intake (2-hour oral iron absorption test). Results: Serum iron level increased constantly within 2 hours after oral iron intake, and serum hepcidin level peaked 4 hours after the iron level peaked. In the oral iron absorption test, the hepcidin levels inversely correlated with increased serum iron levels, and hepcidin expression levels of >80 ng/ml completely inhibited the increase in iron absorption. Conclusion: This study suggests that hepcidin expression may be a strong mediator to regulate iron absorption and that performing an oral iron absorption test with hepcidin may help improve oral iron dosing schedules in patients undergoing hemodialysis. Key Words: hepcidin, ferroportin, divalent metal transporter 1, iron absorption, ferric citrate Almost all patients on maintenance hemodialysis have iron deficiency anemia because of blood loss. The amount of iron loss has been estimated to be 1.5 to 2.0 g/year (1). Thus, adequate iron supplementation, typically requiring non-physiological intravenous iron administration, has become routine for hemodialysis patients (2), because oral iron supplementation has been shown to be unable to maintain adequate iron stores (3-5). However, the adequate iron stores in patients and the efficacy of the physiological iron absorption route in the intestine are controversial. The physiological properties of iron metabolism 1) 1)Kohzaburo Department Fujikawa-Yamamoto of Advanced Medicine, Kanazawa Medical University Division of Cell Graduate Medicine, School Research of Medical Institute Science, of Medical Uchinada, Science, Ishikawa Kanazawa , Medical Japan University, Uchinada, Ishikawa , 2) Department Japan of Internal Medicine, Mizuho Hospital, Ishikawa, Japan Corresponding author:kohzaburo Fujikawa-Yamamoto Accepted: November March 14, 30, in humans are characterized by the absence of active excretory mechanisms for iron and the regulation of body iron content by modulation of iron absorption in the duodenum (6). Iron is absorbed by an active transport mechanism comprised of two steps, namely mucosal uptake of iron from the lumen and mucosal transfer of iron to the bloodstream (7). Both steps are regulated by the body s demand for iron. The phenomenon is supported by the transporter molecules divalent metal transporter (DMT-1) and ferroportin (FPN) (8). Iron influx from the intestinal lumen to cells is induced by DMT-1 expression, and iron efflux from cells to the bloodstream is induced by FPN expression. These unique mechanisms for cellular iron uptake and transport have evolved to prevent the inherent toxicity of iron in the promotion of oxidation due to iron overloading (9). However, many broad variations in iron status have been observed among individuals, and accurate 25
2 Ma/Koshino/et al. regulations according to physiological demand remain unknown. Assays for DMT-1 and FPN expression in individual patients are not available in clinical settings. Hepcidin is the main hormone/peptide that regulates plasma iron levels by controlling the iron export function of FPN, thereby regulating iron absorption and distribution (10). Measurement of hepcidin expression level is progressively being validated (11-13). Currently, its clinical value needs to be assessed in different physiological situations. Based on these molecular properties, we aimed to clarify the iron absorption in individual rat models. In previous ferrokinetic studies, iron stable isotopes were used in the analyses of iron absorption in the intestine (7, 14-16). However, in the clinical field, isotopes are of no practical use; thus, an alternative method that does not use isotopes is expected to detect iron absorption in individual cases. The aims of this study were to quantify the magnitude of iron absorption under different hepcidin levels and to develop a new method to predict the bioavailability of oral iron in individual cases without isotope-labeled iron. In this study, we focused on basic serum hepcidin levels and the changes in serum iron concentration 2 hours after iron intake. Materials and methods 1. Animals Rats (male Sprague-Dawley rats aged 7 to 8 weeks) were obtained from Sankyo Laboratory (Japan) and maintained on a standard rodent diet (iron content: 20 mg/100 g). Synthetic human hepcidin-25 was purchased from Peptide Institute (Japan) and dissolved to appropriate concentrations in phosphate-buffered saline (PBS). Rats received a single intravenous injection of 100 μg of human hepcidin-25. Sucrose iron (40 mg/2 ml; Fesin, Nichi-Iko Pharmaceutical Co., Japan) was used for the injection. Sucrose iron was diluted in 4 mg/ml PBS. Rats received a 4 to 12 mg of iron through intravenous injections of 0.5 ml of iron solution 2 to 6 times a week. A relatively mild protocol of iron overload was chosen to evaluate the relationship between iron absorption and hepcidin expression level under physiological conditions. The control rats received PBS only at the same time points. For inhibiting endogenous hepcidin expression, iron deficiency rats were induced by 1 ml of bloodletting 2 to 6 times a week. For the iron absorption study, the rats were given 10 mg of ferric citrate (FC), including 2.3 mg of iron (Wako, Japan) in 0.5 ml of PBS, by oral gavage at 8:00 am. All the experiments were approved by the animal research committee of Kanazawa Medical University. 2. Blood parameter measurement The rats were anesthetized by using 30% (v/v) isoflurane and killed by exsanguination. Whole blood samples were collected by abdominal aortic puncture for measurements of serum iron level, unsaturated iron-binding capacity (UIBC) and serum hepcidin level. Serum iron level and UIBC were measured by using 2-nitroso-5(N-sulfopropylamino) phenolhydrochloride and ascorbic acid. Serum hepcidin level was measured by using liquid chromatography coupled with tandem mass spectroscopy with reversed phase extraction (Medical Care Proteomics Biotechnology Ltd., Japan) (11). 3. Statistical analysis Statistical analyses were performed by using Statistical package for Social Science(SPSS) Statistics 22 (IBM, USA). The Student t test was used to compare groups of parametric data. Simple linear regression analysis was used to examine the relationship between serum hepcidin levels and changes in serum iron level 2 hours after iron intake. Variables that were not normally distributed were log transformed before the analysis. Data are presented herein as mean ± standard error of the mean. Statistical significance was defined when the p value was <0.05. Results 1. Serum iron levels after oral iron intake In a time-course study, the rats (n=45 rats) were administered 10 mg of FC by oral gavage at 8:00 am and killed at 0, 0.5, 1, 2, 3, 6, 9, 12, and 24 hours after FC intake (n = 5 rats in each group). The onset of the increase in serum iron level after FC intake was quite rapid (Fig 1). Serum iron and transferrin saturation levels (TSAT) increased within 30 minutes and reached the maximum value (488 ± 57.6 μg/dl, 95 ± 2.1%) 2 hours after iron intake (Fig 1A,B). In the rats on a normal diet, the mean pretreatment serum iron concentration was 236 ± 39.5 μg/dl. Thereafter, the serum iron level decreased to its baseline value. On the other hand, the serum hepcidin level gradually increased to its maximum value (56.9 ± 10.5 ng/ml) 4 hours after the serum iron level peaked (Fig 1C). To clarify whether the rats maintained the circadian rhythm of serum iron, their serum iron levels were measured at 8:00, 14:00, and 20:00 (n = 5 rats in each group). The serum iron levels were high in the morning and low in the evening (Fig 2). Under consideration of the circadian rhythm in the rats, all of the rats received FC at 8:00 am. Based on these data, the change in serum iron level at 2 hours after oral iron intake was substituted for iron absorption, which was named as 2-hour oral iron absorption test (2-h OIAT). 26
3 Regulation of Iron Absorption by Hepcidin Fig 2. Diurnal Variations in Serum Iron Concentration in the Normal Rats with Free Access to Food n = 5 rats in each group. *Significantly differs from that at the starting point at 8:00 am (p < 0.05). Fig 1. The 24-hour Serum Iron Levels After Intake of 10 mg of Ferric citrate (FC) in the Normal Rats The rats (n=45 rats) were given 10 mg of FC by oral gavage at 8:00 am and killed 0, 0.5, 1, 2, 3, 6, 9, 12, and 24 hours after FC intake (n = 5 rats in each group). A, serum iron; B, transferrin saturation levels (TSAT); C, hepcidin. *Significantly differs from that at the starting point at 0 hour (p < 0.05). 2. Effects of exogenous hepcidin expression on 2-h OIAT results To study the acute effect of exogenous hepcidin expression, the rats were injected intravenously with 0-, 25-, 50-, and 100-μg doses of human hepcidin-25 at 7:00 am, given 10 mg of FC by oral gavage at 8:00 am, and then killed at 10:00 am (n = 5 rats in each group). Increasing the hepcidin-25 dose resulted in a progressive decrease in serum iron concentration (Fig 3A). In the 2-h OIAT, the rats given 100 μg of hepcidin-25 showed significantly lower serum iron levels than the control rats (268 ± 47 μg/dl vs 501 ± 28 μg/dl, p<0.05). Serum human hepcidin-25 concentration was dependent on the amount of hepcidin-25 injected (Fig 3B). Fig 3. Effect of Exogenous Human Hepcidin-25 on 2-Hour Oral Iron Absorption Test results To study the acute effect of exogenous hepcidin, 0-, 25-, 50-, and 100- mg doses of human hepcidin-25 were injected intravenously at 7:00 am, 10 mg of ferric citrate was administered at 8:00 am, and the rats were killed at 10:00 am (n = 5 rats in each group). *Significantly differs from that of the normal controls (p < 0.05). 3. Effects of endogenous hepcidin expression on 2-h OIAT results To suppress endogenous hepcidin expression, 10 rats were bled 1 ml of whole blood per day, 5 times a week (iron deficiency group). To stimulate endogenous hepcidin expression, 20 rats were given 4 or 12 mg of iron through 2 mg of iron injection per day, 2 or 6 times a week (mild and severe iron loading groups, n = 10 27
4 Ma/Koshino/et al. Fig 4. Effect of Endogenous Hepcidin on 2-Hour Oral Iron Absorption Test results To suppress the endogenous hepcidin expression, 10 rats were bled 1 ml of whole blood per day, 5 times a week (iron deficiency group). To stimulate 20 rats, 4- or 12-mg of iron was administered through 2 mg of iron injection per day, 2 or 6 times a week (mild and severe iron loading groups, n = 10 rats in each group). The controls were given only saline (n = 10 rats). *Significantly differs from the 2-hour oral iron absorption test (2-h OIAT) results of the normal controls (p < 0.05). Fig 5. Effect of Increased Hepcidin Level After the First Oral Iron Intake on the Second Iron Intake The rats were given a second 10-mg dose of ferric citrate at 2, 3, or 6 hours after the first iron intake (n = 5 rats in each group). *Significantly differs from the first 2-hour oral iron absorption test (2-h OIAT) result (8:00 am; p < 0.05). rats in each group). The controls had saline only (10 rats). After 2 days of treatment holiday, the 40 rats were divided into 2-h OIAT and control groups, received 10 mg of FC or saline by oral gavage at 8:00 am, and then killed at 10:00 am. As expected, the hepcidin levels were significantly reduced in the iron deficiency group (2.2 ± 1.5 ng/ml, p<0.05) and significantly increased in the iron loading groups (67.5 ± 6 ng/ml in the mild group and 120 ± 24 in the severe group, p<0.05, p<0.05, respectively) when compared with the control group (26.3 ± 5.3 ng/ml; Figure 4B). Baseline serum iron levels were significantly increased in the iron deficiency group when compared with the severe iron loading group (Figure 4A). The serum iron level in the 2-h OIAT was significantly reduced in the iron loading groups when compared with the control group (245.7 ± 22.9 in the mild group, ± 17.3 in the severe group, p<0.05, p<0.05, respectively, and ± 57.6 ng/ml in the control group). There was no significant difference in serum iron levels between the iron deficiency and control groups. 4. Effect of endogenous hepcidin expression after the first oral iron intake on the second iron intake The effect of serial iron intake on iron absorption was examined because increase in hepcidin level peaked at 6 hours after the first oral intake (Fig 1). The rats received a second 10-mg dose of FC by oral gavage at 2, 3, or 6 hours after first iron intake (n = 5 rats in each group). The serum iron levels in the 2-h OIAT were significantly reduced at 6 hours when compared with the control at 8:00 am (384 ± 33 μg/dl vs 488±57.6 μg/dl, p<0.05; Fig 5). 5. Changes in serum iron level induced by 2-h OIAT in the individual rats Next, the effects of endogenous hepcidin expression on iron absorption in iron deficiency, control and iron loading groups (Fig 5) were confirmed by using 2-h OIAT in the individual rats, which had various hepcidin levels. To induce various hepcidin levels, 14 rats bloodletting (2 ml in 3 rats and 28
5 Regulation of Iron Absorption by Hepcidin Fig 6. Inverse Correlations Between Serum Hepcidin Levels and Change in Serum Iron Level in the 2-Hour Oral Iron Absorption Test The inset shows the correlation between serum hepcidin level and the Ln of the change in serum iron level. n = 17, y = 0.054x , R 2 = 0.91, p < ml in another 3 rats) or iron injections ( 2 mg in 3 rats, 4 mg in 2 rats, and 6 mg in 3 rats) was performed during 7 days, and 3 rats had no treatments. The 0.5- ml first blood samples at 8:00 am and second blood samples after 2h-OIAT were collected from all of the rats. Serum iron levels were compared between the first and second samples in the individual rats. The result of the linear regression analysis as shown in Figure 6 indicate that serum hepcidin levels correlated inversely with the change in serum iron level (r = 0.89, p = 0.003). No iron absorption was observed with 80 ng/ml hepcidin level. Discussion The results of our study show that increased serum iron level 2 hours after iron intake is a useful alternative to ferrokinetic analysis using radiolabeled iron for evaluating iron absorption. In addition, our study shows that the increased serum iron levels inversely correlated with basic serum hepcidin levels. The serum iron levels of the rats reflects the circadian rhythm, and the iron levels were high in the early morning and low in the late evening, similarly to those described in previous reports (17, 18). Accordingly, the rats were administered FC at 8:00 am in our study. Although we did not use a radioisotope as a ferrokinetic study, the serum iron concentration was rapidly increased within 30 minutes and peaked constantly at 2 hours after iron intake apart from the circadian rhythm. Furthermore, the onset of iron absorption in the duodenum was extremely rapid. Wheby et al (7) reported that radiolabeled iron was detected in rat bodies as early as 15 seconds after the iron reached the closed loop of the duodenum and varied in peak levels at 1 hour. These findings implied that increased serum iron level may reflect iron absorption just after influx from the stomach to the duodenum and that the 2-hour iron absorption test may be useful for the evaluation of iron absorption in individual cases. High correlation was observed between the absorption of isotopelabeled iron and the change in serum iron level 6 hours after intake of 100 mg of iron in humans (19). Rivera et al (20) reported that hepcidin accumulated in the FPN-rich organs, namely the liver, spleen, and duodenum. They also reported that the rapid action 29
6 Ma/Koshino/et al. of a single 50-μg dose of human hepcidin-25 administered to mice makes human hepcidin-25 an appealing agent for the prevention of iron release via FPN from iron-storing organs, which consequently shows hypoferric effect within 1 hour. Laftah et al (21) reported that administration of exogenous human hepcidin-25 significantly reduced the mucosal uptake and transfer to the body in mice given isotope-labeled iron. In our study, a single 100-μg dose of exogenous human hepcidin-25 inhibited the increase in serum iron in the 2-h OIAT, which might reflect iron absorption. Although we did not measure the DMT-1 expression, hepcidin may reduce iron absorption by both inhibiting enterocyte DMT-1 transcription and binding to FPN on the enterocyte basolateral membrane (22, 23). Correlation has been reported between endogenous serum hepcidin level and iron absorption (15, 16, 24, 25). Cao et al (15) reported that radiolabeled ferrokinetic studies in rats revealed that liver hepcidin mrna expression inversely correlated with nonheme iron absorption, although their trials were far from clinical application in individual cases. Others (16, 24, 25) reported that plasma hepcidin is a modest predictor of dietary iron bioavailability in healthy men and women with iron statuses ranging from iron deficiency to iron sufficiency. Eschbach et al (14) reported the quantitative relationship between serum level of ferritin, which is a regulator of hepcidin expression via bone morphogenetic protein (BMP) 6 (26), and iron absorption in healthy subjects and patients undergoing long-term dialysis. In all the aforementioned previous studies, iron absorption was evaluated by measuring the amount of isotopic iron incorporated into red blood cells or in whole blood at 2 weeks after ingestion of isotope-labeled iron. The methods are accurate but difficult to implement in individual subjects. Although our method is simple and takes only 2 hours to perform, our findings about the correlation between baseline serum hepcidin levels and changes in serum iron levels in the 2-h OIAT were similar to the results of the previous studies. Our method is simple and provides a means for studying iron absorption without the use of isotope-labeled iron. Furthermore, based on the inverse correlation curve, we can infer the upper limit of hepcidin to inhibit iron absorption completly in patients undergoing hemodialysis. In this regard, much more studies are necessary in clinical fields. In the present study, oral iron loading increased circulating hepcidin level, which in turn affected iron absorption, followed by a secondary iron intake. Transferrin receptor (TFR) 2 expression modulates the signal between iron status and hepcidin expression via the Bmp6/Smad pathway (27). This might take 4 hours to induce hepcidin expression from TFR2 activation by the alteration of serum iron level. Reduced efficacy of a second iron supplementation by the increased hepcidin level may act as a feedback mechanism to limit iron efflux into plasma. Furthermore, the amount of oral iron intake is a main factor of the inhibition of iron uptake via DMT-1 (28). DMT-1 expression is regulated by intracellular ironregulatory proteins, which is regulated by the amount of intracellular iron. When oral iron is loaded, DMT-1 expression is reduced via the iron-regulatory protein pathway and then iron uptake is blocked. We did not perform additional measures after 9 hours and thus could not clarify whether further decrease in serum iron level occurred after the 2-h OIAT. Further studies are needed to analyze the mechanisms of iron absorption via hepcidin and DMT-1 expressions. In the previous studies, oral iron supplementation was unable to maintain adequate iron stores and treat iron deficiency in patients undergoing hemodialysis (3-5). Subsequently, the use of intravenous iron injection in patients with end-stage renal disease has become widespread. Oral iron supplementation often causes gastric irritation, nausea, and constipation, which may decrease treatment adherence and longterm efficacy. High hepcidin levels induced by severe ferritinemia block iron absorption. FC was recently developed as a phosphate binder. Treatment with FC can induce increases in iron parameters while maintaining hemoglobin levels, with a safety profile and without decreased drug adherence. In this situation, prediction of the bioavailability of oral iron may be important in making oral iron dosing schedules for individual patients undergoing hemodialysis who have low iron absorption, probably because of excessive iron stores and high hepcidin levels induced by intravenous iron injection, low levels of erythropoiesis or both. Conclusion Our data suggest that hepcidin level may be the main regulating factor of iron absorption in the intestine. Based on the relationship between hepcidin and serum iron levels 2 hours after iron intake, a new method for ferrokinetics can be developed in order to analyze iron absorption without isotope and to speculate the reason for the lack of iron absorption. The application of the 2-h OIAT in clinical fields is expected in the future. At the start of hemodialysis, a blood sample is drawn for measurement of serum iron and hepcidin-25 levels before FC ingestion and again a small amount of blood is drawn for serum iron measurement 2 hours after oral iron intake. The present study suggests that inducing high hepcidin levels (>80 ng/ml) minimizes fractional iron absorption. The 2-h OIAT may support alternate-day 30
7 Regulation of Iron Absorption by Hepcidin supplementation. This analytical system can be applied in clinical fields in order to estimate the efficacy of oral iron administration in individual cases. It can also be established as a standard method for determining the upper-limit hepcidin level for inhibiting iron accumulation in different physiological and/or pathological situations. This study was self-funded by Kanazawa Medical University. We have greatly benefited from Takanori Tatsuno, PhD. and professor Yasuhito Ishigaki. We are also gratefull to the management staff, Ms. Satomi Okura for her cooperation. Conflict of interest One author (N.T.) is the founder of Medical Care Proteomics Biotechnology Co., Ltd. The other authors declare that they have no competing interests. References 1. Lindsay RM, Burton JA, Edward N et al: Dialyzer blood loss. Clin Nephrol 1973; 1: KDOQI: KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: Besarab A, Coyne DW: Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010; 6: Macdougall IC, Tucker B, Thompson J et al: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: Tinawi M, Martin KJ, Bastani B: Oral iron absorption test in patients on CAPD: comparison of ferrous sulfate and a polysaccharide ferric complex. Nephron 1996; 74: Ganz T: Systemic iron homeostasis. Physiol Rev 2013; 93: Wheby MS, Jones LG, Crosby WH: Studies on iron absorption: intestinal regulatory mechanisms. J Clin Invest 1964; 43: Fleming RE, Ponka P: Iron overload in human disease. N Engl J Med 2012; 366: Rolfs A, Hediger MA: Metal ion transporters in mammals: structure, function and pathological implications. J Physiol 1999; 518(Pt 1): Nemeth E, Tuttle MS, Powelson J et al: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: Murao N, Ishigai M, Yasuno H et al: Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/ selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007; 21: Tomosugi N, Kawabata H, Wakatabe R et al: Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006; 108: Ravasi G, Pelucchi S, Trombini P et al: Hepcidin expression in iron overload diseases is variably modulated by circulating factors. PLoS One 2012; 7: e Eschbach JW, Cook JD, Scribner BH et al: Iron balance in hemodialysis patients. Ann Intern Med 1977; 87: Cao C, Thomas CE, Insogna KL et al: Duodenal absorption and tissue utilization of dietary heme and nonheme iron differ in rats. J Nutr 2014; 144: Zimmermann MB, Troesch B, Biebinger R et al: Plasma hepcidin is a modest predictor of dietary iron bioavailability in humans, whereas oral iron loading, measured by stable-isotope appearance curves, increases plasma hepcidin. Am J Clin Nutr 2009; 90: Dale JC, Burritt MF, Zinsmeister AR: Diurnal variation of serum iron, ironbinding capacity, transferrin saturation, and ferritin levels. Am J Clin Pathol 2002; 117: Lynch SR, Simon M, Bothwell TH et al: Circadian variation in plasma iron concentration and reticuloendothelial iron release in the rat. Clin Sci Mol Med 1973; 45: Hoppe M, Hulthén L, Hallberg L: The validation of using serum iron increase to measure iron absorption in human subjects. Br J Nutr 2004; 92: Rivera S, Nemeth E, Gabayan V et al: Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportincontaining organs. Blood 2005; 106: Laftah AH, Ramesh B, Simpson RJ et al: Effect of hepcidin on intestinal iron absorption in mice. Blood 2004; 103: Mena NP, Esparza A, Tapia V et al: Hepcidin inhibits apical iron uptake in intestinal cells. Am J Physiol Gastrointest Liver Physiol 2008; 294: G Yamaji S, Sharp P, Ramesh B et al: Inhibition of iron transport across human intestinal epithelial cells by hepcidin. Blood 2004; 104: Roe MA, Collings R, Dainty JR et al: Plasma hepcidin concentrations significantly predict interindividual variation in iron absorption in healthy men. Am J Clin Nutr 2009; 89: Young MF, Glahn RP, Ariza-Nieto M et al: Serum hepcidin is significantly associated with iron absorption from food and supplemental sources in healthy young women. Am J Clin Nutr 2009; 89: Feng Q, Migas MC, Waheed A et al: Ferritin upregulates hepatic expression of bone morphogenetic protein 6 and hepcidin in mice. Am J Physiol Gastrointest Liver Physiol 2012; 302: G Corradini E, Rozier M, Meynard D et al: Iron regulation of hepcidin despite attenuated Smad1,5,8 signaling in mice without transferrin receptor 2 or Hfe. Gastroenterology 2011; 141: Frazer DM, Wilkins SJ, Becker EM et al: A rapid decrease in the expression of DMT1 and Dcytb but not Ireg1 or hephaestin explains the mucosal block phenomenon of iron absorption. Gut 2003; 52:
YEAR III Pharm.D Dr. V. Chitra
YEAR III Pharm.D Dr. V. Chitra Anemia can be defined as a reduction in the hemoglobin,hematocrit or red cell number. In physiologic terms an anemia is any disorder in which the patient suffers from tissue
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More information2011 ASH Annual Meeting Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia. December 12, 2011
211 ASH Annual Meeting Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia December 12, 211 Hepcidin is Central Regulator of Iron Homeostasis Hepcidin is liver-expressed,
More informationHemodialysis patients with endstage
Insights into Achieving Target Hemoglobin Levels: Increasing the Serum Ferritin Parameter Scott Bralow, DO Dr. Scott Bralow is the Medical Director of the Renal Center of Philadelphia. Evidence suggests
More informationComparison of methods to asses mineral bioavailability (in vitro vs in vivo)
Comparison of methods to asses mineral bioavailability (in vitro vs in vivo) Ann-Sofie Sandberg Dept of Chemical and Biological Engineering/Food Science Chalmers University of Technology Gothenburg, Sweden
More informationDiscovery. Hepcidin Today. Hepcidin: discovery June 2000: Man: Plasma ultrafiltrate Liver Expressed Antimicrobial Peptide
Hepcidin Today Rachel van Swelm 10 05 2018 ISLH www.radboud ironcenter.com; www.hepcidinanalysis.com Discovery Hepcidin: discovery June 2000: Man: Plasma ultrafiltrate Liver Expressed Antimicrobial Peptide
More informationClinical Study Serum Hepcidin Levels and Reticulocyte Hemoglobin Concentrations as Indicators of the Iron Status of Peritoneal Dialysis Patients
International Nephrology Volume 2012, Article ID 239476, 7 pages doi:10.1155/2012/239476 Clinical Study Serum Hepcidin Levels and Reticulocyte Hemoglobin Concentrations as Indicators of the Iron Status
More informationFor more information about how to cite these materials visit
Author: John Williams, M.D., Ph.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Non-commercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationNext-Generation Biomarkers for Iron Status
Applications/End Users Baetge EE, Dhawan A, Prentice AM (eds): Next-Generation Nutritional Biomarkers to Guide Better Health Care. Nestlé Nutr Inst Workshop Ser, vol 84, pp 59 69, (DOI: 10.1159/000436955)
More informationBMP6 and BMP4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-hjv
BMP6 and BMP4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-hjv Y.J. Shi and X.T. Pan Affiliated Taicang Hospital of Suzhou University, Taicang, Jiangsu, China
More informationLong-term iron accumulation in dialysis patients treated with ferric citrate hydrate: a single-center, 80-week retrospective study in Japan
Hiratsuka et al. Renal Replacement Therapy (2017) 3:37 DOI 10.1186/s41100-017-0118-7 RESEARCH Open Access Long-term iron accumulation in dialysis patients treated with ferric citrate hydrate: a single-center,
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationOral Iron Safe, Effective, and Misunderstood Duke Debates 2017
Oral Iron Safe, Effective, and Misunderstood Duke Debates 2017 John Strouse, MD, PhD Instructor (temp) Medicine and Pediatrics Director, Adult Sickle Cell Program April 20, 2017 1 Disclosures I have no
More informationBMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice
SUPPLEMENTARY MATERIALS BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice Elena Corradini, Paul J. Schmidt, Delphine Meynard, Cinzia Garuti, Giuliana
More informationPatients with Chronic Hepatitis C May be More Sensitive to Iron Hepatotoxicity than Patients with HFE-Hemochromatosis
ORIGINAL ARTICLE Patients with Chronic Hepatitis C May be More Sensitive to Iron Hepatotoxicity than Patients with HFE-Hemochromatosis Hisao Hayashi 1, Alberto Piperno 2, Naohisa Tomosugi 3, Kazuhiko Hayashi
More informationExploring the Mechanisms by which Increasing Dietary Protein Induces Iron Transporter Expression and Improves Intestinal Iron Absorption
University of Connecticut DigitalCommons@UConn Doctoral Dissertations University of Connecticut Graduate School 12-10-2013 Exploring the Mechanisms by which Increasing Dietary Protein Induces Iron Transporter
More informationPlasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease
original article http://www.kidney-international.org & 29 International Society of Nephrology see commentary on page 873 Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in
More informationIntroduction 5/2/2013 IRON RELATED GENES AND OXIDATIVE STRESS IN NON- ALCOHOLIC STEATOHEPATITIS. Iron Physiology. Iron Physiology
// IRON RELATED GENES AND OXIDATIVE STRESS IN NON- ALCOHOLIC STEATOHEPATITIS DIANA MOYA, MD PEDIATRIC GASTROENTEROLOGY FELLOW DIGESTIVE DISEASES & NUTRITION CENTER MAY,. Iron Physiology. /NAFLD. Iron Metabolism
More informationSerum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation
The Journal of International Medical Research 2011; 39: 1961 1967 Serum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation Y XU, XQ DING, JZ ZOU, ZH LIU, SH JIANG AND
More informationIron-Sensing Proteins that Regulate Hepcidin and Enteric Iron Absorption
Annu. Rev. Nutr. 2010. 30:149 71 First published online as a Review in Advance on April 20, 2010 The Annual Review of Nutrition is online at nutr.annualreviews.org This article s doi: 10.1146/annurev.nutr.012809.104801
More informationIron metabolism and medical needs: a view from Academia
Iron metabolism and medical needs: a view from Academia Paul M. Tulkens Cellular & Molecular Pharmacology & Centre for Clinical Pharmacy Catholic University of Louvain Brussels, Belgium Iron therapy Master
More informationRELATIONSHIP OF EXCESS IRON TO CHRONIC DISEASE 1. The physiological role of iron and the relationship. of excess iron to chronic disease.
RELATIONSHIP OF EXCESS IRON TO CHRONIC DISEASE 1 The physiological role of iron and the relationship of excess iron to chronic disease Alicia Cone Metro State University of Denver NUT 3140: Human Nutrition
More informationReduced Expression of Ferroportin-1 Mediates Hyporesponsiveness of Suckling Rats to Stimuli That Reduce Iron Absorption
GASTROENTEROLOGY 2011;141:300 309 Reduced Expression of Ferroportin-1 Mediates Hyporesponsiveness of Suckling Rats to Stimuli That Reduce Iron Absorption DEEPAK DARSHAN, SARAH J. WILKINS, DAVID M. FRAZER,
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationOriginal Articles Effect of Lipopolysaccharide and Bleeding on the Expression of Intestinal Proteins Involved in Iron and Haem Transport
Original Articles Effect of Lipopolysaccharide and Bleeding on the Expression of Intestinal Proteins Involved in Iron and Haem Transport ( iron / haem / intestine / Hcp1 / Cybrd1 / lipopolysaccharide )
More informationUnderstanding dietary and fortificant iron: The devil is in the detail
Understanding dietary and fortificant iron: The devil is in the detail Sylvaine Bruggraber Nutritionist In Industry London, 4 th November 2010 Structure 1. Dietary Iron: 2. Fortificant 3. Bioavailability
More informationJournal of American Science 2018;14(10)
Hepcidin Level and Iron Status in End Stage Renal Disease (ESRD) Patients Tarek El Baz 1, Fawzy Hamed 1, Amr Mohab 3, Abdallah Mahmoud, Magdy El-Said 1, Osama Khamis 1, Amgad Awad 1, Haytham Sabry 1 and
More informationLaboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth
Laboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth Why does it matter? Over 30% of the Worlds population are anaemic,
More informationHematopoiesis, The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid.
Hematopoiesis, 200 billion new blood cells per day The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid. hematopoietic growth factors, proteins that regulate the proliferation
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationHepcidin as a Novel Biomarker of Congestive Hepatopathy in Advanced Heart Failure Patients
Christine J. Chung Doris Duke Clinical Research Fellow 7/7/2011 Hepcidin as a Novel Biomarker of Congestive Hepatopathy in Advanced Heart Failure Patients I. Study Purpose and Rationale Background: Heart
More informationOral iron absorption test should not be performed with iron drops containing ferric iron
Dan Med J 62/8 August 2015 danish medical JOURNAL 1 Oral iron absorption test should not be performed with iron drops containing ferric iron Stine Linding Andersen 1, 2, Claus Gyrup 1, Aase Handberg 1,
More informationManaging peri-operative anaemiathe Papworth way. Dr Andrew A Klein Royal Papworth Hospital Cambridge UK
Managing peri-operative anaemiathe Papworth way Dr Andrew A Klein Royal Papworth Hospital Cambridge UK Conflicts of interest: Unrestricted educational grants/honoraria from CSL Behring, Brightwake Ltd,
More informationLVHN Scholarly Works. Lehigh Valley Health Network. Nelson Kopyt DO, FASN, FACP Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Efficacy and Safety of Oral Ferric Maltol (FM) in Treating Iron-Deficiency Anemia (IDA) in Patients with Chronic Kidney Disease
More informationBiochimica et Biophysica Acta
Biochimica et Biophysica Acta 1823 (2012) 1434 1443 Contents lists available at SciVerse ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbamcr Review Hepcidin and
More informationCOORDINATION OF IRON AND OXYGEN SIGNALING THROUGH POST- TRANSCRIPTIONAL REGULATION OF HYPOXIA INDUCIBLE FACTOR-2ALPHA MCKALE R.
COORDINATION OF IRON AND OXYGEN SIGNALING THROUGH POST- TRANSCRIPTIONAL REGULATION OF HYPOXIA INDUCIBLE FACTOR-2ALPHA By MCKALE R. DAVIS Bachelor of Science in Nutrition and Dietetics Texas Christian University
More informationThe problem with pumping too much iron
The problem with pumping too much iron Stephen D. Zucker, M.D. Professor of Medicine Director of Hepatology Disclosures NONE* * Would be pleased to entertain any reasonable offer Brief History of Hemochromatosis
More informationTSAT PROJECT Shean Strong, QI Director Lisle Mukai, QI Coordinator
Southern California Renal Disease Council, Inc. ESRD Network 18 TSAT PROJECT Shean Strong, QI Director Lisle Mukai, QI Coordinator TSAT 6255 West Sunset blvd Los Angeles, California i 90028 11/24/2010
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationIRON ABSORTPION IN PREGNANT AND NON-PREGNANT WOMEN AND MECHANISMS OF PLACENTAL IRON TRANSFER
IRON ABSORTPION IN PREGNANT AND NON-PREGNANT WOMEN AND MECHANISMS OF PLACENTAL IRON TRANSFER A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment
More informationReview Article Unexplained Aspects of Anemia of Inflammation
Advances in Hematology Volume 2010, Article ID 508739, 5 pages doi:10.1155/2010/508739 Review Article Unexplained Aspects of Anemia of Inflammation Elizabeth A. Price 1, 2 and Stanley L. Schrier 1 1 Department
More informationRevised: 11/2017 FULL PRESCRIBING INFORMATION: CONTENTS* 10 OVERDOSAGE 1 INDICATIONS AND USAGE 11 DESCRIPTION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AURYXIA safely and effectively. See full prescribing information for AURYXIA. AURYXIA (ferric citrate)
More informationIron-refractory iron deficiency anemia: new molecular mechanisms
http://www.kidney-international.org & 2009 International Society of Nephrology Iron-refractory iron deficiency anemia: new molecular mechanisms Yujie Cui 1,2, Qingyu Wu 1,3 and Yiqing Zhou 1 1 Cyrus Tang
More informationLife Science Journal 2013;10(4)
Short Term Low Dose Intravenous Ascorbic Acid in Functional Iron Deficiency Anemia in Hemodialysis Patients Magdy El-Sharkawy¹, Walid Bichari ¹, Mostafa Kamel ¹ and Hanaa Fathey ² ¹ Internal Medicine and
More informationResearch Article Effects of Pregnancy and Lactation on Iron Metabolism in Rats
BioMed Research International Volume 5, Article ID 535, 9 pages http://dx.doi.org/.55/5/535 Research Article Effects of Pregnancy and Lactation on Iron Metabolism in Rats Guofen Gao, Shang-Yuan Liu, Hui-Jie
More informationUnderstand the physiological determinants of extent and rate of absorption
Absorption and Half-Life Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand Objectives Understand the physiological determinants of extent and rate of absorption
More informationRole of Serum Hepcidin levels in the Diagnosis of Iron Deficiency Anemia in Children in Saudi Arabia
Role of Serum Hepcidin levels in the Diagnosis of Iron Deficiency Anemia in Children in Saudi Arabia Mahmoud Mohamed Elgari*, Al-Oufi F¹, Mohammed alsalmi, M. Kurdi, NA Ibrahim, Abdelgadir Elmugadam College
More informationEffects of darbepoetin alfa and epoetin beta pegol on iron kinetics in hemodialysis patients
Sawa et al. Renal Replacement Therapy (2016) 2:26 DOI 10.1186/s41100-016-0037-z RESEARCH Open Access Effects of darbepoetin alfa and epoetin beta pegol on iron kinetics in hemodialysis patients Jun Sawa
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationSYSTEMIC IRON REGULATION AND ADIPOSE TISSUE INFLAMMATION IN HEALTH AND DISEASE. Xiaoya Ma
SYSTEMIC IRON REGULATION AND ADIPOSE TISSUE INFLAMMATION IN HEALTH AND DISEASE by Xiaoya Ma A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Kinesiology)
More informationClinical Policy: Ferumoxytol (Feraheme) Reference Number: CP.PHAR.165
Clinical Policy: (Feraheme) Reference Number: CP.PHAR.165 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationMECHANISMS OF NON-TRANSFERRIN-BOUND IRON UPTAKE BY HUMAN β CELLS AND THE ROLE OF IRON IN DIABETIC PATHOGENESIS
MECHANISMS OF NON-TRANSFERRIN-BOUND IRON UPTAKE BY HUMAN β CELLS AND THE ROLE OF IRON IN DIABETIC PATHOGENESIS By RICHARD COFFEY A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA
More informationMarch, 2000 Volume 9, No. 1 RESEARCH ODDS & ENDS
Research Notes A C o m p i l a t i o n o f V i t a l R e s e a r c h U p d a t e s o n H u m a n N u t r i t i o n March, 2000 Volume 9, No. 1 RESEARCH ODDS & ENDS As many know, Albion is heavily involved
More informationIron Deficiency, Depression, and Other Affective Disorders in Female State Fair Attendees
Iron Deficiency, Depression, and Other Affective Disorders in Female State Fair Attendees A thesis submitted to the faculty of the University of Minnesota by Kathleen Price In partial fulfillment of the
More informationIron bis-glycine chelate competes for the nonheme-iron absorption pathway 1 3
Iron bis-glycine chelate competes for the nonheme-iron absorption pathway 1 3 Fernando Pizarro, Manuel Olivares, Eva Hertrampf, Dora I Mazariegos, Miguel Arredondo, Angélica Letelier, and Virginia Gidi
More informationINVESTIGATION OF IRON CONCENTRATION, VALENCE, AND SOURCE EFFECTS ON SHORT-TERM IRON (Fe) STATUS AND DRINKING WATER PREFERENCE OF LACTATING DAIRY COWS
INVESTIGATION OF IRON CONCENTRATION, VALENCE, AND SOURCE EFFECTS ON SHORT-TERM IRON (Fe) STATUS AND DRINKING WATER PREFERENCE OF LACTATING DAIRY COWS By Olivia N. Genther A THESIS Submitted to Michigan
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationThe Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants
More informationUp-regulation of hepcidin by interleukin-6 contributes to anemia of inflammation in multicentric Castleman's disease (MCD)
99 Mini Review Up-regulation of hepcidin by interleukin-6 contributes to anemia of inflammation in multicentric Castleman's disease (MCD) Nakazawa-Soken J. Song and Kazuyuki Yoshizaki Immuno-Medical Science,
More informationSeries Editors: Daniel Kamin, MD and Christine Waasdorp Hurtado, MD
NASPGHAN Physiology Lecture Series GI Physiology Module: Absorption of Water and Ions Jason Soden, MD Reviewers: George Fuchs MD: UAMS College of Medicine / Arkansas Children s Hospital Wayne Lencer MD:
More informationDisease Pathogenesis and Research Progression of Renal Anemia
2018 3rd International Conference on Life Sciences, Medicine, and Health (ICLSMH 2018) Disease Pathogenesis and Research Progression of Renal Anemia Yingying Liu, Qi Jiang* Department of Nephrology, China-Japan
More informationIron deficiency in heart failure
Iron deficiency in heart failure Piotr Ponikowski, MD, PhD, FESC Department of Heart Diseases, Wroclaw Medical University Centre for Heart Diseases, Military Hospital, Wroclaw, Poland Objectives Importance
More informationIn Focus - Micronutrients and Obesity: iron deficiency & obesity.
In Focus - Micronutrients and Obesity: iron deficiency & obesity. Ana Carla Cepeda López MD PhD Universidad de Monterrey, Vicerrectoría de Ciencias de la Salud, Departamento de Ciencias Básicas. Monterrey,
More informationThe Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders
UPDATES ON DISORDERS OF IRON UTILIZATION AND DISTRIBUTION The Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders Tomas Ganz 1 and Elizabeta Nemeth 1 1 Department
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationMetabolismo del ferro in condizioni normali e patologiche
Metabolismo del ferro in condizioni normali e patologiche Clara Camaschella Università Vita-Salute e IRCCS San Raffaele, Milano Simposio SIES 41 Congresso Nazionale SIE - Bologna 14-17 ottobre 2007 Metabolismo
More informationClinical Study Serum Prohepcidin Levels Are Lower in Patients with Atrophic Gastritis
Gastroenterology Research and Practice Volume 2013, Article ID 201810, 6 pages http://dx.doi.org/10.1155/2013/201810 Clinical Study Serum Prohepcidin Levels Are Lower in Patients with Atrophic Gastritis
More informationIron Imports. II. Iron uptake at the apical membrane in the intestine
Am J Physiol Gastrointest Liver Physiol 289: G981 G986, 2005; doi:10.1152/ajpgi.00363.2005. Theme Iron Imports. II. Iron uptake at the apical membrane in the intestine Bryan Mackenzie 1 and Michael D.
More informationRama Nada. -Ensherah Mokheemer. 1 P a g e
- 3 - Rama Nada -Ensherah Mokheemer - 1 P a g e Don t forget to refer to page index wherever you see * Quick revision: In the previous lecture we said that: - your body contains 4-5g of iron (4g in females
More informationEFFECT OF DIETARY IRON DEFICIENCY AND OVERLOAD ON ZIP14 EXPRESSION IN RATS
EFFECT OF DIETARY IRON DEFICIENCY AND OVERLOAD ON ZIP14 EXPRESSION IN RATS By HYEYOUNG NAM A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
More informationHepcidin and iron regulation, 10 years later
Review article Hepcidin and iron regulation, 10 years later Tomas Ganz 1 1 Departments of Medicine and Pathology, David Geffen School of Medicine at UCLA, Los Angeles, CA Introduction Under evolutionary
More informationIII. TOXICOKINETICS. Studies relevant to the toxicokinetics of inorganic chloramines are severely
III. TOXICOKINETICS Introduction Studies relevant to the toxicokinetics of inorganic chloramines are severely limited. However, studies done with various chlorinated amino compounds (including organic
More informationJ. clin. Path., 24, Suppl. (Roy. Coll. Path.), 5, in corn or black beans is better absorbed when eaten with either veal or fish (Layrisse,
Haemopoietic factors Iron absorption A. JACOBS Department of Haematology, Welsh National School of Medicine, Cardiff Physiological control over iron balance is normally exercised through the regulation
More informationBMP6 Treatment Compensates for the Molecular Defect and Ameliorates Hemochromatosis in Hfe Knockout Mice
GASTROENTEROLOGY 2010;139:1721 1729 BMP6 Treatment Compensates for the Molecular Defect and Ameliorates Hemochromatosis in Hfe Knockout Mice ELENA CORRADINI,*, PAUL J. SCHMIDT, DELPHINE MEYNARD,* CINZIA
More informationIron deficiency is the most common single cause
An Efficacy, Safety and Tolerability Study of Ferrous Ascorbate and Folic Acid (Phosfomin-XT) in Iron Deficiency Anemia BB Adsul*, Qayum Mukaddam**, Prashant Khandeparkar**, Manoj Naik** Abstract Aim:
More informationIron Regulation of Hepcidin Despite Attenuated Smad1,5,8 Signaling in Mice Without Transferrin Receptor 2 or Hfe
GASTROENTEROLOGY 2011;141:1907 1914 Iron Regulation of Hepcidin Despite Attenuated Smad1,5,8 Signaling in Mice Without Transferrin Receptor 2 or Hfe ELENA CORRADINI,* MOLLY ROZIER, DELPHINE MEYNARD,* ADAM
More informationDetermination of bioavailability
Pharmaceutics 2 Bioavailability Bioavailability is the rate and extent to which an administered drug reaches the systemic circulation. For example, if 100 mg of a drug is administered orally and 70 mg
More informationPharmacokinetics I. Dr. M.Mothilal Assistant professor
Pharmacokinetics I Dr. M.Mothilal Assistant professor DRUG TRANSPORT For a drug to produce a therapeutic effect, it must reach to its target and it must accumulate at that site to reach to the minimum
More informationPHYSIOLOGY AND MOLECULAR BIOLOGY OF DIETARY IRON ABSORPTION
Annu. Rev. Nutr. 2003. 23:283 301 doi: 10.1146/annurev.nutr.23.011702.073139 Copyright c 2003 by Annual Reviews. All rights reserved First published online as a Review in Advance on February 26, 2003 PHYSIOLOGY
More informationNUTRITIONAL CARE IN ANEMIA
االله الرحمن الرحيم بسم NUTRITIONAL CARE IN ANEMIA Nutrition Departement Faculty of Medicine University of North Sumatera Definition Deficit of circulating RBC associated with diminished oxygen-carrying
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important Reminder at
More informationUniversity of Groningen. Iron status and heart failure Klip, IJsbrand Thomas
University of Groningen Iron status and heart failure Klip, IJsbrand Thomas IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationHeme Iron peptide (HIP)
Heme Iron peptide (HIP) 1. Clinical trials referenced for bioavailability and side effects STUDIES SHOWING BIOAVAILABILITY MORE THAN SULFATE (Seligman, Moore, and Schleicher 2000) Study compared Japanese
More informationThe Pennsylvania State University. The Graduate School. Department of Nutritional Sciences
The Pennsylvania State University The Graduate School Department of Nutritional Sciences NEW INSIGHTS INTO INTESTINAL HEME AND NON-HEME IRON ABSORPTION: REGULATION BY DIETARY FACTORS A Dissertation in
More informationDisclosures and Funding
S894 A Phase 1, Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of LJPC-41 (Synthetic Human Hepcidin) in Patients With Iron Overload Ashutosh Lal, 1 Antonio
More informationComorbidities in Heart Failure: Iron Deficiency. Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah
Comorbidities in Heart Failure: Iron Deficiency Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah ACC Middle East Conference 2018 Iron Deficiency in Heart Failure
More informationRole of hepcidin in the pathophysiology and diagnosis of anemia
BLOOD RESEARCH VOLUME 48 ㆍ NUMBER 1 March 2013 REVIEW ARTICLE Role of hepcidin in the pathophysiology and diagnosis of anemia Guido D Angelo Ematologia/Coagulazione, Laboratorio di Chimica-Clinica, Ematologia
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationAssessing Iron Deficiency in Adults. Chris Theberge. Iron (Fe) deficiency remains as one of the major global public health problems for
Assessing Iron Deficiency in Adults Chris Theberge Iron (Fe) deficiency remains as one of the major global public health problems for two reasons. It affects about one fourth of the world s population
More informationI ron is vital for all living organisms because it has essential
648 SMLL INTESTINE Duodenal mrn expression of iron related genes in response to iron loading and iron deficiency in four strains of mice F Dupic, S Fruchon, M ensaid, O Loreal, P rissot, N orot, M P Roth,
More informationHemosiderin. Livia Vida 2018
Hemosiderin Livia Vida 2018 Questions Histochemical caracteristics of the different pigments. Exogenous pigments. Hemoglobinogenic pigments. Causes and forms of jaundice. Hemoglobinogenic pigments. Pathological
More informationZahraa Muneer. Enas Ajarma. Saleem
2 Zahraa Muneer Enas Ajarma Saleem Blood parameters: 1. RBCs count 2. Haematocrit 3. Haemoglobin content In new-born babies all three parameters of blood are higher than in normal adults. This happens
More informationcationic molecule, paracellular diffusion would be thought of as its primary mode of transport across epithelial cells.
ABSTRACT Metformin is the most widely prescribed anti-hyperglycemic agent for Type 2 Diabetes Mellitus (T2DM). Despite its frequent use, the intestinal absorption mechanism of this orally administered
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationSerum hepcidin levels and iron parameters in children with iron deficiency
VOLUME 47 ㆍ NUMBER 4 ㆍ December 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Serum hepcidin levels and iron parameters in children with iron deficiency Hyoung Soo Choi 1, Sang Hoon Song 2, Jae
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationthe only oral supplement so quick and effective:
The Product the only oral supplement so quick and effective: 30 days to increase ferritinemia and syderemia to +50% [90-120 days with common oral supplementation with iron]. After 1 week the subject will
More informationThe role of hepcidin, ferroportin, HCP1, and DMT1 protein in iron absorption in the human digestive tract
Review paper The role of hepcidin, ferroportin, HCP1, and DMT1 protein in iron absorption in the human digestive tract Justyna Przybyszewska 1, Ewa Żekanowska 2 1 Department of Nutrition and Dietetics,
More information